Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab or Nivolumab Combinations in Recurrent and Metastatic MSI-H and non-MSI-H Colon Cancer
2024-516004-42-01Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, daratumumab and relatlimab in colorectal cancer (CRC) (7 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate (ORR) by Investigator assessment in all MSI-H and non-MSI-H subjects. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-516004-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516004-42-01.